Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-2.86 Insider Own2.30% Shs Outstand344.43M Perf Week-3.26%
Market Cap10.42B Forward P/E3.92 EPS next Y7.71 Insider Trans2.72% Shs Float332.63M Perf Month35.65%
Income-988.40M PEG- EPS next Q1.79 Inst Own66.80% Short Float9.93% Perf Quarter6.33%
Sales10.32B P/S1.01 EPS this Y-133.00% Inst Trans20.45% Short Ratio1.09 Perf Half Y-53.78%
Book/sh15.35 P/B1.97 EPS next Y17.94% ROA-2.00% Target Price44.39 Perf Year-87.19%
Cash/sh2.47 P/C12.22 EPS next 5Y11.07% ROE-17.00% 52W Range18.55 - 245.82 Perf YTD-70.24%
Dividend- P/FCF8.00 EPS past 5Y4.40% ROI3.70% 52W High-87.69% Beta0.06
Dividend %- Quick Ratio1.10 Sales past 5Y54.60% Gross Margin74.70% 52W Low63.07% ATR1.67
Employees22000 Current Ratio1.40 Sales Q/Q-68.30% Oper. Margin7.70% RSI (14)63.81 Volatility5.13% 5.90%
OptionableYes Debt/Eq5.87 EPS Q/Q- Profit Margin-9.60% Rel Volume0.63 Prev Close30.83
ShortableYes LT Debt/Eq5.81 EarningsAug 09 BMO Payout- Avg Volume30.20M Price30.25
Recom2.90 SMA2013.72% SMA5026.12% SMA200-43.07% Volume19,027,993 Change-1.88%
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Aug-09-16Reiterated Rodman & Renshaw Buy $90 → $81
Jun-23-16Downgrade JP Morgan Overweight → Neutral
Jun-08-16Reiterated Stifel Buy $65 → $55
Jun-08-16Reiterated RBC Capital Mkts Sector Perform $58 → $33
Jun-08-16Reiterated Mizuho Underperform $18 → $11
May-03-16Reiterated Rodman & Renshaw Buy $105 → $102
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Mar-21-16Downgrade Mizuho Neutral → Underperform $70 → $18
Mar-21-16Downgrade Barclays Overweight → Equal Weight $135 → $34
Mar-16-16Reiterated Stifel Buy $200 → $65
Mar-16-16Reiterated Rodman & Renshaw Buy $150 → $118
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $85 → $69
Mar-16-16Reiterated Canaccord Genuity Hold $75 → $40
Mar-16-16Downgrade Nomura Buy → Neutral $175 → $60
Mar-16-16Downgrade CIBC Sector Perform → Sector Underperform
Aug-29-16 05:41PM  Valeant is sued over Philidor ties, alleged racketeering
05:03PM  Healthcare Winners: Stryker Corp., UnitedHealth Group Inc.
04:35PM  Valeant is being sued under racketeering law over drug price hikes at MarketWatch
03:58PM  Valeant (VRX) Stock Falls on Lawsuit
03:53PM  Valeant Being Sued In NY Federal Court Over Alleged Overcharges
01:07PM  Bill Ackman Comments on Valeant
11:30AM  EYEG: Posisitve Cataract Surgery Data, Initial CMHA-S Clinical Program
10:00AM  [$$] Mylan to launch cut-price generic version of EpiPen at Financial Times
Aug-28-16 07:07AM  Time to Shift Your Focus
Aug-27-16 12:30AM  [$$] Hong Kong Tribunal Rules Against U.S. Short-Seller Andrew Left at The Wall Street Journal
Aug-26-16 07:22PM  MOVES-Pershing Square's Valeant analyst to exit, Ackman sees stock rising
07:02PM  Bill Ackman Discusses Worst Year Ever in Mid-Year Letter
05:48PM  MOVES-Pershing Square's Valeant analyst to exit, Ackman optimistic price
04:24PM  Bill Ackman: Valeant 'One Very Big Mistake'
04:13PM  One of the key men behind Bill Ackman's bet on Valeant is leaving to launch a healthcare startup
02:44PM  Forget Mylan, Buy These 3 Drug Stocks Instead
11:46AM  Bill Ackman: 'We made one very big mistake' with Valeant and lost big time at CNBC
10:04AM  [$$] Hong Kong watchdog finds short seller culpable of market misconduct at Financial Times
08:00AM  Mylan offers price plan to help patients but its programs are still short on details at MarketWatch
07:53AM  Short seller Andrew Left deemed reckless by Hong Kong regulator at MarketWatch
Aug-25-16 01:29PM  [$$] Mylan: pen is not mightier at Financial Times
11:13AM  Here's A Reason Why Valeant (VRX) Stock Is Climbing Today
11:10AM  The maker of the EpiPen is playing another dirty trick right from Martin Shkreli's book
10:39AM  Mallinckrodt Could Be Next in Spotlight Thanks to EpiPen Scrutiny
09:21AM  Valeant's Management Continues To Take The Right Steps
08:31AM  How Mylan And Pfizer Could Cause A Major Biotech Backlash at Forbes
07:28AM  Mylan says it will expand programs that lower EpiPen costs
Aug-24-16 04:06PM  Mylan Falls After Being Called Out on Price Increases -- Should You Worry?
Aug-23-16 06:13PM  Valeant Pays up for New CFO Herendeen at The Wall Street Journal
05:03PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation
03:01PM  4 Big-Name Investment Funds That Strongly Believe in a Valeant Pharmaceuticals Turnaround at Motley Fool
12:39PM  Concordia's Uncanny Comparisons to Valeant Continue (Unfortunately) at The Wall Street Journal
10:30AM  Mylan: In EpiPen Controversy, Shades of Valeant at Barrons.com
10:10AM  Stock Market News for August 23, 2016
09:20AM  Blog Coverage Valeant Pharma Appoints New CEO
08:22AM  Valeants stock soars as investors cheer poaching of Zoetis CFO at MarketWatch
01:00AM  Pharming Convene an Extraordinary General Meeting of Shareholders PR Newswire
12:07AM  [$$] A Window of Opportunity Cracks Open at Valeant at The Wall Street Journal
Aug-22-16 06:54PM  Stocks Calm As Crude Plunges; Busy Day For Medical Sector +8.80%
06:22PM  Concordia Healthcare Says Chunk Of CEO's Shares Sold In Margin Call at Forbes
05:57PM  Why Syngenta, Valeant Pharmaceuticals, and BioMarin Pharmaceutical Jumped Today at Motley Fool
04:35PM  Raging Capital Double-Shorting Valeant, Goes Long AFI, CAVM, Others at Insider Monkey
04:31PM  Valeant Bonds Rise on New CFO Choice at Barrons.com
04:05PM  Valeant Stock Jumps On CFO Appointment, As M&A Hopes Rise
03:41PM  Valeant's C-Suite Sees Another Shake-Up
03:18PM  Valeant Pharmaceuticals: Three Reasons Its New CFO is the Right Choice at Barrons.com
02:45PM  7 Red Flags of an Imminent Company Meltdown
01:16PM  Valeant Pharmaceuticals (VRX) Appoints New CFO, Stock Gains 7.2%
01:16PM  Valeant Shares Rise on New CFO Appointment at TheStreet
12:53PM  What you need to know on Wall Street right now
12:21PM  Valeant, attempting to normalize operations, names new CFO
11:50AM  Why the Market is Cheering Valeant's New CFO at Barrons.com
10:52AM  Executive Shuffling, Bullish Write-ups, and Analyst Rating Changes: Heres Why These 5 Stocks Are Trending at Insider Monkey
10:47AM  [$$] A Window of Opportunity Cracks Open at Valeant at The Wall Street Journal
10:25AM  Valeant Gains Momentum With New CFO Appointment at 24/7 Wall St.
10:21AM  Jim Cramer -- Valeant Investors Should Welcome a High-Quality CFO
10:05AM  Allergan Makes an Eye-Opening Acquisition at Motley Fool
07:39AM  Valeant names Paul Herendeen as its new CFO at MarketWatch
07:39AM  Valeant (VRX) Stock Climbs, Hires Zoetis' Herendeen as CFO
07:00AM  Valeant hires Zoetis's Paul Herendeen as CFO
06:33AM  Valeant names Paul Herendeen as new CFO at MarketWatch
06:11AM  Valeant names former Zoetis executive Paul Herendeen as CFO
06:09AM  Valeant Picks New CFO From Zoetis in Ongoing Company Shakeup at Bloomberg
06:06AM  Valeant poached a new CFO from the animal-health company Zoetis
06:00AM  Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer PR Newswire
06:00AM  Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer CNW Group
Aug-21-16 09:33PM  Valeant Is Said to Hire Zoetis Paul Herendeen as CFO at Bloomberg
09:10PM  Valeant has reportedly poached a new CFO from the animal-health company Zoetis
07:15PM  Pershing Square Cuts Positions to Fight Losses (VRX, ZTS) at Investopedia
02:20PM  [$$] Pharmaceuticals: Staying power at Financial Times
12:04PM  [$$] US doctors waste millions on branded medicines at Financial Times
Aug-20-16 12:01AM  [$$] Hedge Funds Snap Up Banks, Unload Apple at Barrons.com
Aug-19-16 04:19PM  Hunting For Biotech Stocks? Understand The Earnings Formula First
03:41PM  T. Rowe Price Sues Valeant Pharmaceuticals For Fraud (TROW, VRX) at Investopedia
02:42PM  Big Money Really Wants Nothing to Do With Valeant Pharmaceuticals -- Here's Proof at Motley Fool
01:31PM  T. Rowe Price sues Valeant Pharmaceuticals, alleging 'fraudulent scheme' at bizjournals.com
01:28PM  'If you ever saw Wolves of Wall Street well that was sorta what some of us saw at Philidor'
12:27PM  Here's the meltdown Bill Ackman had when he found out what was going on at Valeant
10:33AM  Allergan (AGN) Stock Should Outperform, Analyst Tells CNBC
10:21AM  Valeant Stock Down on Lawsuit by T. Rowe, Alters Credit Loan
10:10AM  Company News for August 19, 2016
08:56AM  A.M. Roundup: Hedge Fund Icon Sees "Biggest Bond Bubble Ever"; Changes At Edward Jones at Barrons.com
12:20AM  [$$] Valeant Again Able to Loosen Debt Terms at The Wall Street Journal
Aug-18-16 05:25PM  CANADA STOCKS-TSX slips as energy boost offset by banks, Valeant
04:34PM  T. Rowe Price sues Valeant over "fraudulent scheme" Reuters
04:00PM  JAIL STOCKS CRASH: Here's what you need to know
03:59PM  [$$] Valeant Able to Loosen Debt Terms at The Wall Street Journal
03:37PM  Valeants Debt Agreement Comes With Freedom to Miss Forecast at Bloomberg
03:06PM  Valeant's Feel-Good Moments Don't Last at Bloomberg
02:37PM  Why T. Rowe Price Is Suing Valeant Now
01:23PM  [$$] T Rowe Price sues Valeant for vast fraud at Financial Times
01:21PM  Valeant (VRX) Stock Falls on T. Rowe Price Lawsuit
01:04PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Financials
12:36PM  Wells Fargo Analyst Maris Weighs In on Valeant (VRX) Lawsuit on CNBC
12:21PM  Oh look, another nasty problem for Valeant
12:14PM  Valeant sued by T. Rowe Price, claiming fraud at MarketWatch
11:50AM  [$$] T. Rowe Price Sues Valeant, Alleging 'Fraudulent Scheme' at The Wall Street Journal
11:43AM  T. Rowe Price sues Valeant
11:31AM  Why Valeant Pharmaceuticals is Tanking at Barrons.com
11:24AM  Valeant Pharmaceuticals Accused of Fraud in T. Rowe Price Suit
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Xifaxan for the treatment of irritable bowel syndrome with diarrhea; Wellbutrin XL for major depressive disorder in adults; Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Clindagel, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Glumetza to improve glycemic control in adults with type 2 diabetes mellitus; PROVENGE for the treatment of prostate cancer; and Jublia for onychomycosis of the toenails. It also provides Nitropress for the immediate reduction of blood pressure of patients in hypertensive crises; Isuprel for heart related treatments; Xenazine for chorea; Uceris to get ulcerative colitis under control; Lotemax gel for post-operative inflammation and pain; Arestin, a subgingival sustained-release antibiotic; PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; Biotrue for healthy contact lens wear; and ReNu Multiplus to lubricate and rewet soft contact lenses. In addition, the company offers Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; various ophthalmic surgical products; SofLens daily disposable contact lenses; Biotrue ONEday lens; Bausch + Lomb Ultra, a contact lens PureVision, a contact lens; and medical device systems for aesthetic applications. Further, it provides Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Metronidazole to treat bacterial infections; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM